Abstract:Weily Soong, 1 Bradley E Chipps, 2 Warner Carr, 3 Jennifer Trevor, 4 Arpan Patel, 5 Nicole Clarke, 6 Donna D Carstens, 5 Christopher S Ambrose 6 1 AllerVie Health, AllerVie Clinical Research, Birmingham, AL, USA; 2 Capital Allergy & Respiratory Disease Center, Sacramento, CA, USA; 3 Allergy & Asthma Associates of Southern California, Food Allergy Center of Southern California, Mission Viejo, CA, USA; 4 Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; 5 BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA; 6 BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA Correspondence: Christopher S Ambrose, BioPharmaceuticals Medical, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA, Tel +1 301-398-4454, Email Purpose: Patients living with severe asthma (SA) experience multiple health-related quality of life (HRQoL) impairments. This study examined HRQoL changes after biologic treatment initiation among a large, real-world cohort of patients with SA. Patients and methods: CHRONICLE is an ongoing observational study of subspecialist-treated adults with SA who receive biologics or maintenance systemic corticosteroids or are uncontrolled on high-dosage inhaled corticosteroids with additional controllers. Patients enrolled February 2018–February 2023 were asked to complete the St. George's Respiratory Questionnaire (SGRQ) every 6 months (total score range of 0– 100 [0=best possible health], meaningful change threshold is a 4-unit reduction in the total score). Changes in SGRQ responses from 6 months before initiation to 12 to 18 months after initiation were summarized. Results: A total of 76 patients completed the SGRQ 0 to 6 months before and 12 to 18 months after biologic initiation. The mean (SD) SGRQ total score decreased from 52.2 (20.6) to 41.9 (23.8), with improvement across the symptoms (− 14.5), activity (− 11.0), and impacts (− 8.3) components. For specific impairments reported by ≥ 50% of patients before biologic initiation, fewer reported each impairment after biologic initiation; the largest reductions were for "Questions about what activities usually make you feel short of breath these days [Walking outside on level ground]" (67% to 43%), "Questions about other effects that your respiratory problems may have on you these days [I feel that I am not in control of my respiratory problems]" (55% to 34%), and "Questions about your cough and shortness of breath these days [My coughing or breathing disturbs my sleep]" (63% to 45%). Conclusion: In this real-world cohort of adults with SA, biologic initiation was associated with meaningful improvements in asthma-related HRQoL. These data provide further insight into the burden SA places on patients and the benefits of biologic treatment. Keywords: observational, real-world, health-related quality of life, St. George's Respiratory Questionnaire An estimated 5% to 10% of individuals with asthma have severe asthma (SA), which is defined by the requirement for high-dosage inhaled corticosteroids and additional controllers. 1,2 As compared with the general asthma patient population, patients with SA experience a disproportionately greater burden of symptoms, exacerbations, and treatment requirements, with a commensurate impact on health-related quality of life (HRQoL). 3,4 Patients with persistently uncontrolled SA despite the use of high-dosage inhaled corticosteroids and additional controllers are potential candidates for biologic treatments, which have been shown to reduce asthma exacerbations and the need for oral corticosteroids (OCS) as well as to improve lung function, symptoms, and HRQoL, although specific demonstrated effects vary across biologics. 5 In their treatment preferences and goals, patients with SA may prioritize HRQoL improvements above other outcomes, including the number and severity of exacerbations. 6 Clinical trials and a small number of real-world studies in SA have shown improvements in HRQoL associated with biologic use. 7–15 However, the few real-world studies conducted in the US were treatment-specific and varied in design, patient population, and assessment instruments. 14,15 The impact of biologic treatments as a class on HRQoL in patients with SA in longer-term real-world settings has not been well described. Thus, the objective of this analysis was to examine changes in HRQoL after approximately 1 year of biologic treatment in a broad, real-world sample of US patients with SA. CHRONICLE (ClinicalTrials.gov: NCT03373045) is an ongoing real-world obser -Abstract Truncated-

Improvement in health-related quality of life questionnaires with biologic treatment in severe asthma and comorbid chronic rhinosinusitis with or without nasal polyposis: a real-life experience

Chronic rhinosinusitis and nasal polyps: the role of generic and specific questionnaires on assessing its impact on patient's quality of life

Sinonasal Outcomes Obtained after 2 Years of Treatment with Benralizumab in Patients with Severe Eosinophilic Asthma and CRSwNP: A "Real-Life" Observational Study

Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis

Quality of life and work functionality in severe asthma patients: the impact of biological therapies

Real-Life Evidence of Mepolizumab Treatment in Chronic Rhinosinusitis with Nasal Polyps: A Multicentric Study

Real-world outcomes on quality-of-life improvement in patients with nasal polyposis treated with mepolizumab. RINOSUR study

Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP

Efficacy of dupilumab in real-life settings: a STROBE study

A Multicentric Study in Northeast Italy

The use of biologics in patients suffering from chronic rhinosinusitis with nasal polyps - a 4-year real life observation

Patient-Reported Outcomes with Benralizumab in Patients with Severe Eosinophilic Asthma and Severe Chronic Rhinosinusitis with Nasal Polyps

Effect of biologic therapies on quality of life in severe asthma: Findings from the PRISM study

Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational Study

Omalizumab Treatment in Uncontrolled Asthma and CRSwNP Patients, with Previous Endoscopic Sinus Surgery, to Improve Quality of Life and Endoscopic Outcomes: a Two-Year Real-Life Study

Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective

Effectiveness and safety profile of mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a tertiary care

Quality of Life Improvements with Biologic Initiation Among Subspecialist-Treated US Patients with Severe Asthma

Practice Patterns of Biologics Prescriptions and Surgery in Chronic Rhinosinusitis With Nasal Polyps

Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL)

Comparison between clinical and cytological findings in chronic rhinosinusitis with nasal polyps treated with Dupilumab